CAMBRIDGE, Mass.–(BUSINESS WIRE)–Ushering in a new era in the treatment of spinal cord injuries (SCI), InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), announced today that world-renowned spinal cord injury (SCI) researcher Edward Wirth, M.D., Ph.D., will join InVivo as its Chief Science Officer (CSO) effective December 5, 2011.
As CSO, Dr. Wirth will lead InVivo’s first human clinical study for acute SCI using the Company’s proprietary scaffold without drugs or cells. With the 10-patient pilot study awaiting FDA approval to begin in early 2012, InVivo’s treatment represents a promising new hope for SCI patients….
http://www.businesswire.com/news/home/20111017005366/en